CBD Monthly Update — August 2020

FDA issues draft guidance on research 

The U.S. Food and Drug Association released the long-awaited “Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research, Draft Guidance for Industry,” including insight into the agency’s thinking on clinical research regulations. Learn more at The National Law Review.

2020 “extinction event” for thousands of CBD brands?

Research from the Brightfield Group forecasts that the crowd of CBD companies will thin substantially this year, with COVID-19 driving a likely “extinction event” for half or more brands. Learn more at Hemp Industry Daily. 

American Heart Association urges DEA to reschedule

 In a new scientific statement, the organization asks the DEA to remove cannabis from the Schedule I list so that it can be widely studied. Learn more at AZmarijuana.com. 

White House meeting with industry advocates

 Though officials haven’t revealed the content of a new enforcement discretion policy, some industry representatives who have been speaking with federal officials are optimistic that such a formal policy will be announced soon. Learn more at Natural Products Insider.

Prices fall, companies seek new consumers

 Driven by falling prices for hemp biomass, reduced production expenses and plans to reach consumers with less disposable income as unemployment numbers remain high during the pandemic, U.S. CBD products prices have dropped. Learn more at Hemp Industry Daily.

Want to receive these updates directly to your inbox each month? Sign up here, and also get a copy of Demystifying CBD, one question at a time.